ATI Free cash flow decreased by 67.3% to $73.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 150.1%, from -$145.80M to $73.00M. Over 2 years (FY 2022 to FY 2025), Free cash flow shows an upward trend with a 88.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$69.50M | -$185.00M | -$243.20M | -$34.00M | $77.30M | $293.90M | -$345.60M | -$158.20M | -$164.60M | $40.90M | -$41.80M | $333.60M | -$145.80M | $89.40M | $167.00M | $223.10M | $73.00M |
| QoQ Change | — | -166.2% | -31.5% | +86.0% | +327.4% | +280.2% | -217.6% | +54.2% | -4.0% | +124.8% | -202.2% | +898.1% | -143.7% | +161.3% | +86.8% | +33.6% | -67.3% |
| YoY Change | — | — | — | +51.1% | +141.8% | — | -42.1% | -304.7% | +52.4% | — | +73.6% | — | +11.4% | +118.6% | +499.5% | -33.1% | +150.1% |